AU
AXSM icon

AlphaGrep UK’s Axsome Therapeutics AXSM Stock Holding History

AlphaGrep UK’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
940
-1,104
-54% -$239K 0.07% 629
2026
Q1 		$345K Buy
2,044
+481
+31% +$83.1K 0.1% 442
2025
Q4 		$285K Buy
+1,563
New +$218K 0.1% 459

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AlphaGrep UK's AXSM Position: Q2 2026 in Review

AlphaGrep UK reduced its Axsome Therapeutics (AXSM) stake by 54% in Q2 2026, selling an estimated $239K and leaving 940 shares worth $230K. The position accounts for 0.07% of the portfolio, ranked #629.

AlphaGrep UK first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $345K in Q1 2026. 461 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • AlphaGrep UK held 940 shares of Axsome Therapeutics worth $230K as of Q2 2026.
  • AlphaGrep UK sold 1,104 Axsome Therapeutics shares in Q2 2026, an estimated $239K.
  • Axsome Therapeutics made up 0.07% of AlphaGrep UK's portfolio in Q2 2026, its #629 holding.
  • AlphaGrep UK first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • AlphaGrep UK's Axsome Therapeutics position peaked at $345K in Q1 2026.
  • 461 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.